公开(公告)号：US20160193174A1

公开(公告)日：2016-07-07

申请号：US14915799

申请日：2014-09-03

申请人： ENZYCHEM LIFESCIENCES CORPORATION ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

发明人： Jae Wha KIM ,  Sei-Ryang OH ,  Kyung Seop AHN ,  Ho Bum KANG ,  Jae Mine YOO ,  Tae-Suk LEE ,  JongKoo KANG ,  Hye Kyung KIM ,  Jin Soo YOOK ,  Yong-Hae HAN ,  Ki Young SOHN

IPC分类号： A61K31/231 ,  A61Q19/00 ,  A61K9/00 ,  A61K8/37

CPC分类号： A61K31/231 ,  A23L33/10 ,  A23V2002/00 ,  A61K8/37 ,  A61K9/0014 ,  A61K9/08 ,  A61K47/44 ,  A61K2800/10 ,  A61Q19/00

摘要： The present invention relates to a pharmaceutical composition, functional health food composition, quasi-drug composition, and cosmetic composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing, treating or improving atopic dermatitis. The monoacetyldiacylglycerol compound of the present invention has an excellent effect of suppression of IL-4 and IgE secretion, thereby overcoming side effects of an atopic dermatitis treatment agent currently in use, having no toxicity, and exhibiting an excellent treatment effect, and thus can be useful as a composition for preventing, treating, and ameliorating atopic dermatitis.

摘要翻译： 本发明涉及含有单乙酰二酰基甘油化合物作为预防，治疗或改善特应性皮炎的活性成分的药物组合物，功能保健食品组合物，准药物组合物和化妆品组合物。 本发明的单乙酰基二酰基甘油化合物具有抑制IL-4和IgE分泌的优异效果，从而克服目前使用的特应性皮炎治疗剂的副作用，无毒性，并具有优异的治疗效果，因此可以 可用作预防，治疗和改善特应性皮炎的组合物。

公开(公告)号：US20210002197A1

公开(公告)日：2021-01-07

申请号：US16978873

申请日：2019-03-25

申请人： ENZYCHEM LIFESCIENCES CORPORATION

发明人： Ki Young SOHN ,  Jae Wha KIM ,  Sun Young YOON ,  Chang Hyun YOO ,  Jin Seon JEONG

IPC分类号： C07C41/09 ,  A61P37/02

摘要： Disclosed are a novel 1,2-diacylglycerol compound that useful for improving, preventing or treating inflammation-related diseases by inhibiting overexpression of various inflammatory cytokines such as IL-4 and IL-6 or chemokine CXCL8 related to the migration of inflammatory cells, a method for preparing the same, and an immunomodulator containing the same as an active ingredient. The 1,2-diacylglycerol compound is represented by Chemical Formula 2 in the patent specification.

公开(公告)号：US20180325857A1

公开(公告)日：2018-11-15

申请号：US15775811

申请日：2016-11-14

申请人： ENZYCHEM LIFESCIENCES CORPORATION

发明人： Ki Young SOHN ,  Jae Wha KIM

IPC分类号： A61K31/231 ,  A61P7/06 ,  A61P13/12 ,  A61P7/00 ,  A61K9/48

CPC分类号： A61K31/231 ,  A61K9/48 ,  A61K9/4825 ,  A61K9/4858 ,  A61K31/22 ,  A61K31/355 ,  A61P7/00 ,  A61P7/06 ,  A61P13/12 ,  Y02A50/473

摘要： The present invention provides methods for treating, controlling or mitigating hemolytic uremic syndrome (HUS), comprising administering a monoacetyldiacylglycerol compound to a patient in need thereof, as well as compositions useful therefor.

公开(公告)号：US20210002242A1

公开(公告)日：2021-01-07

申请号：US16977548

申请日：2019-03-08

申请人： ENZYCHEM LIFESCIENCES CORPORATION

发明人： Ki Young SOHN ,  Jae Wha KIM ,  Sun Young YOON ,  Chang Hyun YOO ,  Jin Seon JEONG

IPC分类号： C07D307/32 ,  A23L33/00 ,  A23L29/00 ,  A61P31/04

摘要： Disclosed are a novel diacylglycerol lactone compound for improving immunity and inhibiting infection by promoting neutrophil movement, a preparation method therefor, and an immunostimulator containing same as an active ingredient. The diacyloglycerol lactone compound is represented by chemical formula 1 of the specification. In chemical formula 1, R1 and R2 are respectively N and independently a C2-30 fatty acid group.

公开(公告)号：US20190022047A1

公开(公告)日：2019-01-24

申请号：US16045617

申请日：2018-07-25

申请人： ENZYCHEM LIFESCIENCES CORPORATION ,  KOREA RESEARCH INSTITUTE OF BIO SCIENCE AND BIOTECHNOLOGY

发明人： Jae Wha KIM ,  Sei-Ryang OH ,  Kyung Seop AHN ,  Ho Bum KANG ,  Jae Min SHIN ,  Young Eun KO ,  Tae Suk LEE ,  Myung Hwan KIM ,  Jong Koo KANG ,  Yong-Hae HAN ,  Ki-Young SOHN

IPC分类号： A61K31/231 ,  A61K35/32 ,  A61K31/23 ,  A23L33/10 ,  A61K31/22

摘要： The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

公开(公告)号：US20160151323A1

公开(公告)日：2016-06-02

申请号：US14951353

申请日：2015-11-24

申请人： ENZYCHEM LIFESCIENCES CORPORATION

发明人： Yong-Hae HAN ,  Saeho CHONG ,  Ki-Young SOHN ,  Myung-Hwan KIM ,  Jae Wha KIM

IPC分类号： A61K31/231 ,  A61K9/00 ,  A61K9/48 ,  A61K38/19

摘要： The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.

公开(公告)号：US20210198183A1

公开(公告)日：2021-07-01

申请号：US17047123

申请日：2019-04-19

申请人： ENZYCHEM LIFESCIENCES CORPORATION

发明人： Ki Young SOHN ,  Jae Wha KIM ,  Sun Young YOON ,  Chang Hyun YOO ,  Jin Seon JEONG

IPC分类号： C07C233/20 ,  C07C233/18 ,  C07C233/38 ,  C07C327/28 ,  C07C235/06 ,  C07C69/708 ,  A61P37/06

摘要： Disclosed are a glycerol derivative that is useful for improving, preventing or treating inflammation-related diseases by inhibiting overexpression of various inflammatory cytokines such as IL-4, IL-6 and so on, or chemokine CXCL8 and reducing migration of HL-60 cell lines, preparation method therefor, and an immunomodulator containing the same as active ingredient. It includes a glycerol derivative represented by Chemical formula 2 or 3 in the specification.

公开(公告)号：US20160199338A1

公开(公告)日：2016-07-14

申请号：US14912049

申请日：2014-08-18

申请人： ENZYCHEM LIFESCIENCES CORPORATION ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

发明人： Jae Wha KIM ,  Sei Ryang OH ,  Kyung Seop AHN ,  Ho Bum KANG ,  Beom Su PARK ,  Tae Suk LEE ,  Jong Koo KANG ,  Young Sik JUNG ,  Yong-Hae HAN ,  Ki-Young SOHN

IPC分类号： A61K31/231 ,  A61K9/48 ,  A61K9/00

CPC分类号： A61K31/231 ,  A61K9/0053 ,  A61K9/4825 ,  A61K31/23

摘要： The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.

公开(公告)号：US20160128966A1

公开(公告)日：2016-05-12

申请号：US14936464

申请日：2015-11-09

申请人： ENZYCHEM LIFESCIENCES CORPORATION

发明人： Yong-Hae HAN ,  Saeho CHONG ,  Ki-Young SOHN ,  Myung-Hwan KIM ,  Jae Wha KIM

IPC分类号： A61K31/231 ,  A61K9/00 ,  A61K38/19

摘要： The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.

摘要翻译： 本公开提供了治疗，控制或缓解白细胞减少症（例如中性粒细胞减少）和/或血小板减少症的方法，例如在癌症化疗的情况下，包括施用单乙酰基 - 二酰基 - 甘油化合物，以及可用于其的组合物。

公开(公告)号：US20180296520A1

公开(公告)日：2018-10-18

申请号：US15775810

申请日：2016-11-14

申请人： ENZYCHEM LIFESCIENCES CORPORATION

发明人： Ki Young SOHN ,  Jae Wha KIM

IPC分类号： A61K31/231 ,  A61K9/48 ,  A61P7/00

摘要： The present invention provides methods for treating, controlling or mitigating paroxysmal nocturnal hemoglobinuria (PNH), comprising administering a monoacetyldiacylglycerol compound to a patient in need thereof, as well as compositions useful therefor.